• Diagnosis, Management, and Surveillance for Patients with PALB2, CHEK2, and ATM Gene Mutations.
    • Fencer MG, Krupa KA, Bleich GC, Grumet S, Eladoumikdachi FG, Kumar S, Kowzun MJ, Potdevin LB.
    • Clin Breast Cancer. 2023 Feb 15:S1526-8209(23)00034-4. doi: 10.1016/j.clbc.2023.02.004. Epub ahead of print.
    • Psychological distress and decision-making factors for prophylactic bilateral mastectomy in cancer-unaffected BRCA1/2 pathogenic variant carriers.
    • Isselhard A, Tüchler A, Dick J, Scherer A, Aue V, Schmutzler RK, Rhiem K.
    • Psychooncology. 2023 Feb 12. doi: 10.1002/pon.6111. Epub ahead of print.
    • Factors that influence the management recommendations breast surgeons provide to women with pathogenic variants in moderate penetrance breast cancer susceptibility genes.
    • Vanderwal A, Lewis J, Basil J, Atzinger C, Widmeyer K.
    • J Genet Couns. 2023 Jan 15. doi: 10.1002/jgc4.1674. Epub ahead of print.
    • Postmastectomy breast reconstruction for women with hereditary gastric and breast cancer syndrome.
    • De Lorenzi F, Borelli F, Catapano S, Alessandri-Bonetti M, Sala P, Veronesi P.
    • Eur J Cancer Prev. 2022 Dec 27. doi: 10.1097/CEJ.0000000000000780. Epub ahead of print.
    • Review
    • Psychological factors and the uptake of preventative measures in BRCA1/2 pathogenic variant carriers: results of a prospective cohort study.
    • Dick J, Tüchler A, Brédart A, Vitinius F, Wassermann K, Rhiem K, Schmutzler RK.
    • Hered Cancer Clin Pract. 2022 Dec 19;20(1):38. doi: 10.1186/s13053-022-00244-y.
    • Cost-Effectiveness of Risk-Reducing Surgery for Breast and Ovarian Cancer Prevention: A Systematic Review.
    • Wei X, Oxley S, Sideris M, Kalra A, Sun L, Yang L, Legood R, Manchanda R.
    • Cancers (Basel). 2022 Dec 12;14(24):6117. doi: 10.3390/cancers14246117.
    • Is Sentinel Lymph Node Biopsy Necessary in Patients who Undergo Prophylactic Mastectomy?
    • Madan V, Mamounas EP.
    • Clin Breast Cancer. 2022 Dec 7:S1526-8209(22)00271-3. doi: 10.1016/j.clbc.2022.12.003. Epub ahead of print.
    • Insurance Coverage of Prophylactic Mastectomies: A National Review of the United States.
    • Ha M, Ngaage LM, Finkelstein ER, Klein M, Yang A, Colohan SM, Nurudeen SM, Terhune JH, Slezak S, Rasko YM.
    • Clin Breast Cancer. 2022 Dec 5:S1526-8209(22)00269-5. doi: 10.1016/j.clbc.2022.12.001. Epub ahead of print.
    • Immediate Breast Reconstruction Using the Autologous Dermal Flap.
    • Kaviani A, Ashraf-Ganjouei A, Vasigh M, Zand S, Patocskai E.
    • J Surg Res. 2022 Nov 30;283:713-718. doi: 10.1016/j.jss.2022.11.002. Epub ahead of print.
    • BIA-ALCL Epidemiological Findings From a Retrospective Study of 248 Cases Extracted from Relevant Case Reports and Series: A Systematic Review.
    • Di Pompeo FS, Panagiotakos D, Firmani G, Sorotos M.
    • Aesthet Surg J. 2022 Nov 29:sjac312. doi: 10.1093/asj/sjac312. Epub ahead of print.
    • UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2.
    • Hanson H, Kulkarni A, Loong L, Kavanaugh G, Torr B, Allen S, Ahmed M, Antoniou AC, Cleaver R, Dabir T, Evans DG, Golightly E, Jewell R, Kohut K, Manchanda R, Murray A, Murray J, Ong KR, Rosenthal AN, Woodward ER, Eccles DM, Turnbull C, Tischkowitz M; Consensus meeting attendees, Lalloo F.
    • J Med Genet. 2022 Nov 21:jmg-2022-108898. doi: 10.1136/jmg-2022-108898. Epub ahead of print.
    • Mastectomy with one-stage or two-stage reconstruction in breast cancer: analysis of early outcomes and patient's satisfaction.
    • Angela G, Alessandro P, Alessia T, Michele M, Rossella E, Marco M, Michele T, Giuseppe Massimiliano L, Walter L, Elisabetta P, Paolo PF, Ilaria SL, Giuseppe G, Mario T.
    • Updates Surg. 2022 Nov 19. doi: 10.1007/s13304-022-01416-0. Epub ahead of print.
    • Receipt of Bilateral Mastectomy Among Women With Hereditary Breast Cancer.
    • Reid S, Roberson ML, Koehler K, Shah T, Weidner A, Whisenant JG, Pal T.
    • JAMA Oncol. 2022 Nov 3. doi: 10.1001/jamaoncol.2022.5162. Epub ahead of print.
    • Revision Rate of Direct-to-Implant Breast Reconstruction: Is it Truly a Single-Stage Reconstruction? A Single-Surgeon Experience.
    • Adler N, Carmon E, Houri P.
    • Aesthetic Plast Surg. 2022 Oct 28. doi: 10.1007/s00266-022-03136-7. Epub ahead of print.
    • Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.
    • Sessa C, Balmaña J, Bober SL, Cardoso MJ, Colombo N, Curigliano G, Domchek SM, Evans DG, Fischerova D, Harbeck N, Kuhl C, Lemley B, Levy-Lahad E, Lambertini M, Ledermann JA, Loibl S, Phillips KA, Shimon P; ESMO Guidelines Committee.
    • Ann Oncol. 2022 Oct 19:S0923-7534(22)04193-X. doi: 10.1016/j.annonc.2022.10.004. Epub ahead of print.
    • Why I Chose Preventive Mastectomy.
    • Swirsky N.
    • FORCE. Blog. 2022 Oct 3.
    • ASO Author Reflections: Sentinel Lymph Node Biopsy in BRCA1/2 Germline Pathogenic Variant Carriers Undergoing Risk-Reducing Mastectomy.
    • Ferroum A, Wong SM.
    • Ann Surg Oncol. 2022 Oct;29(11):6669-6670. doi: 10.1245/s10434-022-12013-1. Epub 2022 Jun 16.
    • Commentary
    • Risk-reducing mastectomy decisions among women with mutations in high- and moderate- penetrance breast cancer susceptibility genes.
    • Comeaux JG, Culver JO, Lee JE, Dondanville D, McArthur HL, Quinn E, Gorman N, Ricker C, Li M, Lerman C.
    • Mol Genet Genomic Med. 2022 Oct;10(10):e2031. doi: 10.1002/mgg3.2031. Epub 2022 Aug 25.
    • Controversies and Open Questions in Management of Cancer-Free Carriers of Germline Pathogenic Variants in BRCA1/BRCA2.
    • Bernstein-Molho R, Friedman E, Evron E.
    • Cancers (Basel). 2022 Sep 22;14(19):4592. doi: 10.3390/cancers14194592.
    • Getting Past the Shock of a Previvor Diagnosis and Making a Plan.
    • Swirsky N.
    • FORCE. Blog. 2022 Sep 21.
    • Prophylactic mastectomy and occult malignancy: Surgical and imaging considerations.
    • Thompson JL, Sinco BR, McCaffrey RL, Chang AE, Sabel MS, Dossett LA, Hughes TM, Jeruss JS.
    • J Surg Oncol. 2022 Sep 7. doi: 10.1002/jso.27088. Epub ahead of print.
    • Risk-reducing mastectomy for unaffected women with a strong family history of breast cancer.
    • Willson ML, Srinivasa S, Fatema K, Lostumbo L, Carbine NE, Egger SJ, Goodwin A.
    • Cochrane Database Syst Rev. 2022 Sep 6;9(9):CD015020. doi: 10.1002/14651858.CD015020.pub2.
    • Points to Consider Regarding Risk-Reducing Mastectomy in High-, Moderate-, and Low-Penetrance Gene Carriers.
    • Corso G, Robson ME, Sacchini V.
    • Ann Surg Oncol. 2022 Sep;29(9):5821-5825. doi: 10.1245/s10434-022-11913-6. Epub 2022 May 23.
    • Review, Commentary
    • Optimal breast cancer risk reduction policies tailored to personal risk level.
    • Ergun MA, Hajjar A, Alagoz O, Rampurwala M.
    • Health Care Manag Sci. 2022 Sep;25(3):363-388. doi: 10.1007/s10729-022-09596-2. Epub 2022 Jun 10.
    • Breast cancer in a teenage girl with BRCA mutation: A case report from a low middle-income country.
    • Vohra LM, Ali D, Hashmi SA, Angez M.
    • Int J Surg Case Rep. 2022 Sep;98:107513. doi: 10.1016/j.ijscr.2022.107513. Epub 2022 Aug 13.
    • Eligibility, uptake and response to germline genetic testing in women with DCIS.
    • Turza L, Lovejoy LA, Turner CE, Shriver CD, Ellsworth RE.
    • Front Oncol. 2022 Aug 26;12:918757. doi: 10.3389/fonc.2022.918757.
    • What are the considerations in patient selection and timing of risk-reducing mastectomy?
    • Pederson HJ, Kurian AW, Al Hilli Z.
    • Cleve Clin J Med. 2022 Aug 1;89(8):442-444. doi: 10.3949/ccjm.89a.21114.
    • Risk-reducing mastectomy for women with hereditary breast and ovarian cancer (HBOC): analytical results of data from the Japanese Organization of HBOC.
    • Ohsumi S, Nakamura S, Miyata H, Watanabe C, Den H, Arai M.
    • Jpn J Clin Oncol. 2022 Jul 30:hyac120. doi: 10.1093/jjco/hyac120. Epub ahead of print.
    • Satisfaction and Quality of Life of Healthy and Unilateral Diseased BRCA1/2 Pathogenic Variant Carriers after Risk-Reducing Mastectomy and Reconstruction Using the BREAST-Q Questionnaire.
    • Herold N, Hellmich M, Lichtenheldt F, Ataseven B, Hillebrand V, Wappenschmidt B, Schmutzler RK, Rhiem K.
    • Genes (Basel). 2022 Jul 28;13(8):1357. doi: 10.3390/genes13081357.
    • The Clinical and Psychosocial Outcomes for Women Who Received Unexpected Clinically Actionable Germline Information Identified through Research: An Exploratory Sequential Mixed-Methods Comparative Study.
    • Forrest LE, Forbes Shepherd R, Tutty E, Pearce A, Campbell I, Devereux L, Trainer AH, James PA, Young MA.
    • J Pers Med. 2022 Jul 7;12(7):1112. doi: 10.3390/jpm12071112.
    • Functions of Breast Cancer Predisposition Genes: Implications for Clinical Management.
    • Yoshimura A, Imoto I, Iwata H.
    • Int J Mol Sci. 2022 Jul 5;23(13):7481. doi: 10.3390/ijms23137481.
    • Cost-utility analysis of risk-reducing strategies to prevent breast and ovarian cancer in BRCA-mutation carriers in Switzerland.
    • Bommer C, Lupatsch J, Bürki N, Schwenkglenks M.
    • Eur J Health Econ. 2022 Jul;23(5):807-821. doi: 10.1007/s10198-021-01396-9. Epub 2021 Nov 12.
    • Cancer risk-reducing surgery: Brazilian society of surgical oncology guideline part 1 (gynecology and breast).
    • Carneiro VCG, Gifoni ACLVC, Mauro Rossi B, Andrade CEMDC, Lima FT, Galvão HCR, Casali da Rocha JC, Silva Barreto LSD, Ashton-Prolla P, Guindalini RSC, Farias TP, Andrade WP, Fernandes PHS, Ribeiro R, Lopes A, Tsunoda AT, Azevedo BRB, Marins CAM, Oliveira Uchôa DNA, Dos Santos EAS, Fernández Coimbra FJ, Dias Filho FA, Lopes FCO, Fernandes FG, Ritt GF, Laporte GA, Guimaraes GC, Feitosa E Castro Neto H, Dos Santos JC, de Carvalho Vilela JB, Meinhardt Junior JG, Cunha JRD, Medeiros Milhomem L, da Silva LM, Maciel LF, Ramalho NM, Leite Nunes R, Guido de Araújo R, de Assunção Ehrhardt R, Delgado Bocanegra RE, Silva Junior TC, Oliveira VR, Silva Surimã W, de Melo Melquiades M, Ribeiro HSC, Oliveira AF.
    • J Surg Oncol. 2022 Jul;126(1):10-19. doi: 10.1002/jso.26812.
    • Guideline
    • Medical knowledge and information needs among women with pathogenic variants in moderate-risk genes for hereditary breast cancer attending genetic counseling at an academic hospital in Germany-A qualitative approach.
    • Stracke C, Lemmen C, Rhiem K, Schmutzler R, Kautz-Freimuth S, Stock S.
    • J Genet Couns. 2022 Jun;31(3):698-712. doi: 10.1002/jgc4.1536. Epub 2021 Nov 26.
    • Differences in Willingness to Undergo BRCA1/2 Testing and Risk Reducing Surgery among the General Public, Cancer Patients, and Healthcare Professionals: A Large Population-Based Survey.
    • Chang YJ, Cho S, Joo J, Ryu KH, Lee S, Cho J, Lim MC, Jung SY, Han JH, Lee ES, Kong SY.
    • J Pers Med. 2022 May 18;12(5):818. doi: 10.3390/jpm12050818.
    • Clinical Impact of Pathogenic Variants in DNA Damage Repair Genes beyond BRCA1 and BRCA2 in Breast and Ovarian Cancer Patients.
    • Espinel W, Champine M, Hampel H, Jeter J, Sweet K, Pilarski R, Pearlman R, Shane K, Brock P, Westman JA, Kipnis L, Sotelo J, Chittenden A, Culver S, Stopfer JE, Schneider KA, Sacca R, Koeller DR, Gaonkar S, Vaccari E, Kane S, Michalski ST, Yang S, Nielsen SM, Bristow SL, Lincoln SE, Nussbaum RL, Esplin ED.
    • Cancers (Basel). 2022 May 13;14(10):2426. doi: 10.3390/cancers14102426.
    • Combining Breast and Ovarian Operations Increases Complications.
    • Henn D, Barrera JA, Sivaraj D, Lin JQ, Rizk NM, Ma I, Gurtner GC, Lee GK, Nazerali RS.
    • Plast Reconstr Surg. 2022 May 1;149(5):1050-1059. doi: 10.1097/PRS.0000000000008984. Epub 2022 Mar 2.
    • Phylogenetic Analysis IDs Subset of De Novo Tumors Unrelated to Primary DCIS.
    • Ray T.
    • GenomeWeb. Disease Areas. Cancer. 2022 Apr 11.
    • Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits.
    • Schrijver LH, Mooij TM, Pijpe A, Sonke GS, Mourits MJE, Andrieu N, Antoniou AC, Easton DF, Engel C, Goldgar D, John EM, Kast K, Milne RL, Olsson H, Phillips KA, Terry MB, Hopper JL, van Leeuwen FE, Rookus MA.
    • J Natl Cancer Inst. 2022 Apr 11;114(4):540-552. doi: 10.1093/jnci/djac004.

    Commentary:

    Oral Contraceptives and BRCA Cancer: A Balancing Act.

    • Attitude towards hereditary cancer risk management among women with cancer in Taiwan.
    • Fang SY, Hsieh LL, Hung CF, Hung FH, Peng HP, Yang AS, Wang YA.
    • Support Care Cancer. 2022 Apr;30(4):3625-3632. doi: 10.1007/s00520-021-06742-4. Epub 2022 Jan 14.
    • Uptake Rates of Risk-Reducing Surgeries for Women at Increased Risk of Hereditary Breast and Ovarian Cancer Applied to Cost-Effectiveness Analyses: A Scoping Systematic Review.
    • Simões Corrêa Galendi J, Kautz-Freimuth S, Stock S, Müller D.
    • Cancers (Basel). 2022 Mar 31;14(7):1786. doi: 10.3390/cancers14071786.
    • Pre-pectoral breast reconstruction: early and long-term safety evaluation of 146 unselected cases of the early pre-pectoral era of a single-institution, including cases with previous breast irradiation and post-mastectomy radiation therapy.
    • Bernini M, Meattini I, Saieva C, Becherini C, Salvestrini V, Visani L, Stocchi G, Bellini C, Lorenzetti V, Sordi S, Nori J, De Benedetto D, Desideri I, Bianchi S, Livi L, Orzalesi L.
    • Breast Cancer. 2022 Mar;29(2):302-313. doi: 10.1007/s12282-021-01314-0. Epub 2021 Nov 14.
    • Indications des mastectomies de réduction de risque en dehors du risque avéré de prédisposition héréditaire : recommandations du Collège national des gynécologues et obstétriciens français (CNGOF) [Non-genetic indications for risk reducing mastectomies: Guidelines of the National College of French Gynecologists and Obstetricians (CNGOF)].
    • Mathelin C, Barranger E, Boisserie-Lacroix M, Boutet G, Brousse S, Chabbert-Buffet N, Coutant C, Daraï E, Delpech Y, Duraes M, Espié M, Fornecker L, Golfier F, Grosclaude P, Hamy AS, Kermarrec E, Lavoué V, Lodi M, Luporsi É, Maugard CM, Molière S, Seror JY, Taris N, Uzan C, Vaysse C, Fritel X.
    • Gynecol Obstet Fertil Senol. 2022 Feb;50(2):107-120. French. doi: 10.1016/j.gofs.2021.12.005. Epub 2021 Dec 14.
    • Guideline, [Article in French]
    • Uptake and timing of bilateral and contralateral risk-reducing mastectomy in women with Li-Fraumeni syndrome.
    • Siegel A, Bremer RC, Klein WMP, Savage SA, Loud JT, Khincha PP.
    • Breast Cancer Res Treat. 2022 Jan;191(1):159-167. doi: 10.1007/s10549-021-06410-5. Epub 2021 Oct 15.
    • Is there an increasing trend of risk-reducing prophylactic mastectomy procedure in preventing breast cancer among women?
    • Arslan B, Tazeoglu D, Dag A, Berkesoglu M, Özdemir AA.
    • Turk J Surg. 2021 Dec 31;37(4):347-354. doi: 10.47717/turkjsurg.2021.4963.
    • Effect of Inquiry-Based Stress Reduction on Well-being and Views on Risk-Reducing Surgery Among Women With BRCA Variants in Israel: A Randomized Clinical Trial.
    • Landau C, Novak AM, Ganz AB, Rolnik B, Friedman E, Lev-Ari S.
    • JAMA Netw Open. 2021 Dec 1;4(12):e2139670. doi: 10.1001/jamanetworkopen.2021.39670.
    • Uptake of bilateral-risk-reducing-mastectomy: Prospective analysis of 7195 women at high-risk of breast cancer.
    • Evans DG, Gandhi A, Wisely J, Clancy T, Woodward ER, Harvey J, Highton L, Murphy J, Barr L, Howell SJ, Lalloo F, Harkness EF, Howell A.
    • Breast. 2021 Dec;60:45-52. doi: 10.1016/j.breast.2021.08.015. Epub 2021 Aug 26.
    • Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe.
    • Marmolejo DH, Wong MYZ, Bajalica-Lagercrantz S, Tischkowitz M, Balmaña J; extended ERN-GENTURIS Thematic Group 3.
    • Eur J Med Genet. 2021 Dec;64(12):104350. doi: 10.1016/j.ejmg.2021.104350. Epub 2021 Oct 1.
    • Review
    • Bilateral Risk-Reducing Prophylactic Mastectomies in an Unaffected BRCA1 Carrier Using Dermal Sling and Implant.
    • Gupta S, Kadayaprath G, Gupta N, Barthwal V.
    • Indian J Surg Oncol. 2021 Dec;12(Suppl 2):355-358. doi: 10.1007/s13193-021-01370-0. Epub 2021 Jun 16.
    • Case report
    • Breast Cancer Surgery: New Issues.
    • Magnoni F, Alessandrini S, Alberti L, Polizzi A, Rotili A, Veronesi P, Corso G.
    • Curr Oncol. 2021 Oct 11;28(5):4053-4066. doi: 10.3390/curroncol28050344.
    • Prepectoral breast reconstruction: an ideal approach to bilateral risk-reducing mastectomy.
    • Maruccia M, Elia R, Tedeschi P, Gurrado A, Moschetta M, Testini M, Giudice G.
    • Gland Surg. 2021 Oct;10(10):2997-3006. doi: 10.21037/gs-21-339.
    • Data on Utility in Cost-Utility Analyses of Genetic Screen-and-Treat Strategies for Breast and Ovarian Cancer.
    • Simões Corrêa Galendi J, Vennedey V, Kentenich H, Stock S, Müller D.
    • Cancers (Basel). 2021 Sep 29;13(19):4879. doi: 10.3390/cancers13194879.
    • Bilateral DIEP flap breast reconstruction with simultaneous unilateral nipple-sparing mastectomy - case report.
    • Lukasz U, Piotr G, Maria M.
    • Folia Med Cracov. 2021 Sep 29;61(3):115-124. doi: 10.24425/fmc.2021.138955.
    • Case report
    • Surgical Management of Hereditary Breast Cancer.
    • Berger ER, Golshan M.
    • Genes (Basel). 2021 Aug 31;12(9):1371. doi: 10.3390/genes12091371.
    • ASO Author Reflections: Prophylactic Nipple-Sparing Mastectomy as an Effective Risk-Reducing Strategy for BRCA Mutation Carriers.
    • Garstka M, Smith BL.
    • Ann Surg Oncol. 2021 Aug 13. doi: 10.1245/s10434-021-10588-9. Epub ahead of print.
    • Commentary
    • Attitudes toward Risk-Reducing Mastectomy and Risk-Reducing Salpingo-oophorectomy among Young, Unmarried, Healthy Women in Korea.
    • Park B, Kim D, Kim J, Lee BY, Yoon J, Kim SW.
    • Cancer Res Treat. 2021 Aug 9. doi: 10.4143/crt.2021.449. Epub ahead of print.
    • Surgical management of BRCA pathogenic variant carriers with breast cancer: a recent literature review and current state of the art.
    • Terribile DA, Mason EJ, Murando F, DI Leone A, Sanchez AM, Scardina L, Magno S, Franco A, D'Archi S, Natale M, Lucci Cordisco E, Masetti R, Franceschini G.
    • Minerva Surg. 2021 Aug 2. doi: 10.23736/S2724-5691.21.09009-2. Epub ahead of print.
    • Review
    • Influential Factors on Risk-reduction Mastectomy in a High-risk Breast Cancer Population With Genetic Predispositions.
    • Wei G, Kumar A, Lee MC, Wang X.
    • Clin Breast Cancer. 2021 Aug;21(4):e427-e433. doi: 10.1016/j.clbc.2021.01.008. Epub 2021 Jan 19.
    • Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).
    • Tischkowitz M, Balmaña J, Foulkes WD, James P, Ngeow J, Schmutzler R, Voian N, Wick MJ, Stewart DR, Pal T; ACMG Professional Practice and Guidelines Committee.
    • Genet Med. 2021 Aug;23(8):1416-1423. doi: 10.1038/s41436-021-01151-8. Epub 2021 May 11.
    • Guidelines
    • Interactions of BRCA1-mutated Breast Cancer Cell Lines with Adipose-derived Stromal Cells (ADSCs).
    • Plangger A, Haslik W, Rath B, Neumayer C, Hamilton G.
    • J Mammary Gland Biol Neoplasia. 2021 Jul 6. doi: 10.1007/s10911-021-09493-4. Epub ahead of print.
    • Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudal observational study.
    • Safra T, Waissengrin B, Gerber D, Bernstein-Molho R, Klorin G, Salman L, Josephy D, Chen-Shtoyerman R, Bruchim I, Frey MK, Pothuri B, Muggia F.
    • Gynecol Oncol. 2021 Jun 22:S0090-8258(21)00489-3. doi: 10.1016/j.ygyno.2021.06.009. Epub ahead of print.
    • Why I’m Choosing to Keep My Breasts (For Now).
    • Kingery R.
    • FORCE. Blog. 2021 Jun 11.
    • Clinical practice guideline of BRCA1/2 testing for patients with breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guideline 2021.
    • Xie F, Wang S.
    • Chin Med J (Engl). 2021 Jun 4;134(13):1516-1518. doi: 10.1097/CM9.0000000000001587.
    • An evaluation of memory and attention in BRCA mutation carriers using an online cognitive assessment tool.
    • Kotsopoulos J, Kim SJ, Armel S, Bordeleau L, Foulkes WD, McKinnon W, Panchal S, Cohen SA, Sun S, Sun P, McKetton L, Troyer AK, Narod SA.
    • Cancer. 2021 Jun 2. doi: 10.1002/cncr.33654. Epub ahead of print.
    • Risk-Reducing Mastectomy and Reconstruction Following Prophylactic Breast Irradiation: Hope Sustained.
    • Ben David MA, Evron E, Rasco AF, Shai A, Corn BW.
    • Cancers (Basel). 2021 May 30;13(11):2694. doi: 10.3390/cancers13112694.
    • Evaluation of online Spanish and English health materials for preventive mastectomy. are we providing adequate information?
    • Del Valle DD, Pardo JA, Maselli AM, Valero MG, Fan B, Seyidova N, James TA, Lee BT.
    • Breast Cancer Res Treat. 2021 May;187(1):1-9. doi: 10.1007/s10549-021-06171-1. Epub 2021 Mar 15.
    • Review
    • Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers.
    • Toss A, Tenedini E, Piombino C, Venturelli M, Marchi I, Gasparini E, Barbieri E, Razzaboni E, Domati F, Caggia F, Grandi G, Combi F, Tazzioli G, Dominici M, Tagliafico E, Cortesi L.
    • Genes (Basel). 2021 Apr 21;12(5):616. doi: 10.3390/genes12050616.
    • Management of patients with BRCA mutation from the point of view of a breast surgeon.
    • Riis ML.
    • Ann Med Surg (Lond). 2021 Apr 16;65:102311. doi: 10.1016/j.amsu.2021.102311.
    • Clinical management among individuals with variant of uncertain significance in hereditary cancer: A systematic review and meta-analysis.
    • Makhnoon S, Bednar EM, Krause KJ, Peterson SK, Lopez-Olivo MA.
    • Clin Genet. 2021 Apr 12. doi: 10.1111/cge.13966. Epub ahead of print.
    • Review
    • Controversies in Hereditary Cancer Management.
    • AlHilli MM, Pederson HJ.
    • Obstet Gynecol. 2021 Apr 8. doi: 10.1097/AOG.0000000000004364. Epub ahead of print.
    • Bilateral nipple-sparing mastectomy and breast reconstruction in BRCA1 mutation-positive simultaneous bilateral breast cancer: A case study.
    • Yoneyama K, Nakagawa M, Hara A.
    • Int J Surg Case Rep. 2021 Apr;81:105788. doi: 10.1016/j.ijscr.2021.105788. Epub 2021 Mar 17.
    • Understanding Breast Implant Risks.
    • Spittal K.
    • FORCE. XRAY. 2021 Mar 30.
    • Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
    • Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, Goggins M, Hutton ML; CGC, Karlan BY, Khan S, Klein C, Kohlmann W; CGC, Kurian AW, Laronga C, Litton JK, Mak JS; LCGC, Menendez CS, Merajver SD, Norquist BS, Offit K, Pederson HJ, Reiser G; CGC, Senter-Jamieson L; CGC, Shannon KM, Shatsky R, Visvanathan K, Weitzel JN, Wick MJ, Wisinski KB, Yurgelun MB, Darlow SD, Dwyer MA.
    • J Natl Compr Canc Netw. 2021 Jan 6;19(1):77-102. doi: 10.6004/jnccn.2021.0001.
    • Why is appropriate healthcare inaccessible for many European breast cancer patients? - The EBCC 12 manifesto.
    • Cardoso F, MacNeill F, Penault-Llorca F, Eniu A, Sardanelli F, Nordström EB, Poortmans P.
    • Breast. 2021 Jan 2;55:128-135. doi: 10.1016/j.breast.2020.12.010. Epub ahead of print.
    • Genetic Testing Challenges in Oncology: Woman Without High Breast Cancer Risk Recommended Surgery.
    • Ray T.
    • Precision Oncology News. 2020 Dec 22.
    • My Previvor Journey: My Robotic Mastectomy.
    • Mallonee R.
    • FORCE. Blog. 2020 Dec 7.
    • Genotype-first approach to the detection of hereditary breast and ovarian cancer risk, and effects of risk disclosure to biobank participants.
    • Leitsalu L, Palover M, Sikka TT, Reigo A, Kals M, Pärn K, Nikopensius T, Esko T, Metspalu A, Padrik P, Tõnisson N.
    • Eur J Hum Genet. 2020 Nov 23. doi: 10.1038/s41431-020-00760-2. Epub ahead of print.
    • Expanded Panel Testing Uncovered My ATM Mutation.
    • Horton M.
    • FORCE. Blog. 2020 Nov 23.
    • I am a PALB2 Previvor.
    • Dinschel A.
    • FORCE. Blog. 2020 Nov 19.
    • Population-Wide Hereditary Breast, Ovarian Cancer Screening in Younger Women is Cost-Effective.
    • [No author given]
    • Clinical OMICs. Molecular Dx. 2020 Nov 17.

    Original research:

    Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.

    • Clinical outcomes of patients after nipple-sparing mastectomy and reconstruction based on the expander/implant technique.
    • Toh U, Takenaka M, Iwakuma N, Akagi Y.
    • Surg Today. 2020 Nov 13. doi: 10.1007/s00595-020-02175-4. Epub ahead of print.
    • Concurrent Prophylactic Mastectomy, Immediate Reconstruction, and Salpingo-Oophorectomy in High-Risk Patients: A Case Series.
    • D'Abbondanza JA, George R, Kives S, Musgrave MA.
    • Plast Surg (Oakv). 2020 Nov;28(4):243-248. doi: 10.1177/2292550320928551. Epub 2020 Jun 4.
    • Knowing about an inherited BRCA mutation improves outcomes for women with breast cancer.
    • [No author given]
    • FORCE. XRAY. 2020 Oct 26.

    Original research:

    Presymptomatic Awareness of Germline Pathogenic BRCA Variants and Associated Outcomes in Women With Breast Cancer.

    • Surgical and Systemic Treatment of Hereditary Breast Cancer: A Mini-Review With a Focus on BRCA1 and BRCA2 Mutations.
    • Pouptsis A, Swafe L, Patwardhan M, Stavraka C.
    • Front Oncol. 2020 Oct 20;10:553080. doi: 10.3389/fonc.2020.553080. PMID: 33194613; PMCID: PMC7607003.
    • Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States.
    • Guzauskas GF, Garbett S, Zhou Z, Spencer SJ, Smith HS, Hao J, Hassen D, Snyder SR, Graves JA, Peterson JF, Williams MS, Veenstra DL.
    • JAMA Netw Open. 2020 Oct 1;3(10):e2022874. doi: 10.1001/jamanetworkopen.2020.22874.

    Press: Population-Wide Hereditary Breast, Ovarian Cancer Screening in Younger Women is Cost-Effective. (Clinical OMICs)

    • Time trends in uptake rates of risk-reducing mastectomy in Israeli asymptomatic BRCA1 and BRCA2 mutation carriers.
    • Galmor L, Bernstein-Molho R, Sklair-Levy M, Madoursky-Feldman D, Zippel D, Laitman Y, Friedman E.
    • Breast Cancer Res Treat. 2020 Sep 30. doi: 10.1007/s10549-020-05949-z. Epub ahead of print.
    • Preferences for breast cancer prevention among women with a BRCA1 or BRCA2 mutation.
    • Mansfield CA, Metcalfe KA, Snyder C, Lindeman GJ, Posner J, Friedman S; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Lynch HT, Narod SA, Evans DG, Liede A.
    • Hered Cancer Clin Pract. 2020 Sep 29;18:20. doi: 10.1186/s13053-020-00152-z.
    • Presymptomatic Awareness of Germline Pathogenic BRCA Variants and Associated Outcomes in Women With Breast Cancer.
    • Hadar T, Mor P, Amit G, Lieberman S, Gekhtman D, Rabinovitch R, Levy-Lahad E.
    • JAMA Oncol. 2020 Sep 1;6(9):1460-1463. doi: 10.1001/jamaoncol.2020.2059.

    Research news: Study Sees Survival Boost For BRCA1/2 Carriers Tested Before Breast Cancer Diagnosis. (GenomeWeb)

    Research news: 'Knowledge Is Power': Knowing BRCA1/2 Status Tied to Survival. (Medscape)

    Research news: Knowing about an inherited BRCA mutation improves outcomes for women with breast cancer. (FORCE. XRAY.)

    • Management of early breast cancer during the COVID-19 pandemic in Brazil.
    • Cavalcante FP, Novita GG, Millen EC, Zerwes FP, de Oliveira VM, Sousa ALL, Freitas Junior R.
    • Breast Cancer Res Treat. 2020 Aug 16. doi: 10.1007/s10549-020-05877-y. Epub ahead of print.
    • Risk for breast cancer and management of unaffected individuals with non-BRCA hereditary breast cancer.
    • Wood ME, McKinnon W, Garber J.
    • Breast J. 2020 Aug 2. doi: 10.1111/tbj.13969. Epub ahead of print.
    • Review
    • Re: Risk-reducing mastectomy: a case series of 124 procedures in Brazilian patients.
    • Goncalves R.
    • Breast Cancer Res Treat. 2020 Aug;182(3):763-764. doi: 10.1007/s10549-020-05742-y. Epub 2020 Jun 13.
    • Letter, Commentary

    Original research:

    Risk-reducing mastectomy: a case series of 124 procedures in Brazilian patients.

    • Management of breast cancer risk in BRCA1/2 mutation carriers who are unaffected with cancer.
    • Collins JM, Isaacs C.
    • Breast J. 2020 Jul 11. doi: 10.1111/tbj.13970. Epub ahead of print.
    • Review
    • How to Prepare for a Mastectomy Amid COVID and Other Life Events.
    • Wheaton J.
    • FORCE Blog. 2020 Jul 8.
    • Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
    • Cragun D, Weidner A, Tezak A, Clouse K, Pal T.
    • Breast Cancer Res Treat. 2020 Jul;182(2):421-428. doi: 10.1007/s10549-020-05699-y. Epub 2020 May 22.
    • Study: What is the risk for contralateral breast cancer in women with an inherited BRCA1, BRCA2 or TP53 mutation?
    • [No author given]
    • FORCE. XRAYS. 2020 Jun 6.

    Original research:

    Risk of Contralateral Breast Cancer in Women with and without Pathogenic Variants in BRCA1, BRCA2, and TP53 Genes in Women with Very Early-Onset (<36 Years) Breast Cancer.

    • The DIEP Flap as Well-established Method of Choice for Autologous Breast Reconstruction with a Low Complication Rate - Retrospective Single-centre 10-Year Experience.
    • Munder B, Andree C, Witzel C, Fertsch S, Stambera P, Schulz T, Fleischer O, Hagouan M, Grüter L, Aufmesser B, Staemmler K, Kornetka J, Aldeeri M, Seidenstücker K, Abu-Ghazaleh A, Wolter A.
    • Geburtshilfe Frauenheilkd. 2020 Jun;80(6):628-638. doi: 10.1055/a-1116-2102. Epub 2020 Apr 16.
    • Risk-reducing mastectomy: a case series of 124 procedures in Brazilian patients.
    • Frasson AL, Lichtenfels M, de Souza AAB, Vollbrecht B, Falcone AB, Frasson MARM, Barbosa F.
    • Breast Cancer Res Treat. 2020 May;181(1):69-75. doi: 10.1007/s10549-020-05582-w. Epub 2020 Mar 25.

    Letter, Commentary:

    Re: Risk-reducing mastectomy: a case series of 124 procedures in Brazilian patients.

    • Canadian cost-effectiveness model of BRCA-driven surgical prevention of breast/ovarian cancers compared to treatment if cancer develops.
    • Hurry M, Eccleston A, Dyer M, Hoskins P
    • Int J Technol Assess Health Care. 2020 Apr;36(2):104-112. doi: 10.1017/S0266462319003519.
    • Lumbar Flap versus the Gold Standard: Comparison to the DIEP Flap.
    • Opsomer D, Vyncke T, Depypere B, Stillaert F, Blondeel P, Van Landuyt K.
    • Plast Reconstr Surg. 2020 Apr;145(4):706e-714e. doi: 10.1097/PRS.0000000000006681.
    • Oncoplastic Procedures in Preparation for Nipple-Sparing Mastectomy and Autologous Breast Reconstruction: Controlling the Breast Envelope.
    • Momeni A, Kanchwala S, Sbitany H.
    • Plast Reconstr Surg. 2020 Apr;145(4):914-920. doi: 10.1097/PRS.0000000000006657.
    • Risk-reducing mastectomy in germline CDH1 mutation carriers: Pathologic findings.
    • Gianella CA, Bendito B, Iglesias C, Bengoechea MP, Miñón C, Ruiz A.
    • Breast J. 2020 Mar;26(3):583-584. doi: 10.1111/tbj.13604. Epub 2019 Sep 20.
    • Risk of Contralateral Breast Cancer in Women with and without Pathogenic Variants in BRCA1, BRCA2, and TP53 Genes in Women with Very Early-Onset (<36 Years) Breast Cancer.
    • Hyder Z, Harkness EF, Woodward ER, Bowers NL, Pereira M, Wallace AJ, Howell SJ, Howell A, Lalloo F, Newman WG, Smith MJ, Evans DG.
    • Cancers (Basel). 2020 Feb 7;12(2):378. doi: 10.3390/cancers12020378.

    Research news: Study: What is the risk for contralateral breast cancer in women with an inherited BRCA1, BRCA2 or TP53 mutation? (FORCE XRAYS)

    • Bilateral Breast Reconstruction With Profunda Artery Perforator Flaps and Immediate Implant Augmentation.
    • Chu CK, DeFazio M, Largo RD, Ross M.
    • Aesthet Surg J Open Forum. 2020 Jan 14;2(1):ojz036. doi: 10.1093/asjof/ojz036.
    • Patient-Reported Outcome Measures may optimize shared decision-making for cancer risk management in BRCA mutation carriers.
    • van Egdom LSE, de Kock MA, Apon I, Mureau MAM, Verhoef C, Hazelzet JA, Koppert LB.
    • Breast Cancer. 2019 Dec 12. doi: 10.1007/s12282-019-01033-7. [Epub ahead of print]
    • BRCA and Motherhood: A Matter of Time and Timing.
    • Possick C, Kestler-Peleg M.
    • Qual Health Res. 2019 Dec 7:1049732319885113. doi: 10.1177/1049732319885113. [Epub ahead of print]
    • Prophylactic nipple-sparing mastectomy in young previvors: Examining decision-making, reconstructive outcomes, and patient satisfaction in BRCA+ patients under 30.
    • Salibian AA, Bekisz JM, Frey JD, Miller B, Choi M, Karp NS.
    • Breast J. 2019 Nov 17. doi: 10.1111/tbj.13692. [Epub ahead of print]
    • Geisinger MyCode® detects BRCA2 mutation prior to abdominal panniculectomy allowing for DIEP flap breast reconstruction.
    • Kauffman CA.
    • Case Reports Plast Surg Hand Surg. 2019 Nov 6;6(1):145-147. doi: 10.1080/23320885.2019.1684824. eCollection 2019.
    • Is prophylactic mastectomy justified in women without BRCA mutation?
    • Rutgers EJT.
    • Breast. 2019 Nov;48 Suppl 1:S62-S64. doi: 10.1016/S0960-9776(19)31126-9.
    • Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer.
    • [No author given]
    • National Institute for Health and Care Excellence (UK): Clinical Guidelines; 2013 Jun. [Last Update: November 2019.]
    • Cost effectiveness of bilateral risk-reducing mastectomy and salpingo-oophorectomy.
    • Schrauder MG, Brunel-Geuder L, Häberle L, Wunderle M, Hoyer J, Csorba R, Reis A, Schulz-Wendtland R, Beckmann MW, Lux MP.
    • Eur J Med Res. 2019 Sep 14;24(1):32. doi: 10.1186/s40001-019-0391-8.
    • Use of Mammographic Measurements to Predict Complications After Nipple-Sparing Mastectomy in BRCA Mutation Carriers.
    • Park KU, Weiss A, Rosso K, Yi M, Hunt K, Kuerer H, Hanson SE, Candelaria R, Tevis S, Thompson A.
    • Ann Surg Oncol. 2019 Aug 9. doi: 10.1245/s10434-019-07704-1. [Epub ahead of print]
    • Warranting the decision-maker, not the decision: How healthcare practitioners evaluate the legitimacy of patients' unprompted requests for risk-reducing mastectomy.
    • Brown SL, Beesley H, Holcombe C, Saini P, Salmon P.
    • Patient Educ Couns. 2019 Aug;102(8):1446-1451. doi: 10.1016/j.pec.2019.03.007. Epub 2019 Mar 18.
    • Screening and surgical prophylaxis for hereditary cancer syndromes with high risk of endometrial and ovarian cancer.
    • Bercow AS, Eisenhauer EL.
    • J Surg Oncol. 2019 Jul 29. doi: 10.1002/jso.25645. [Epub ahead of print]
    • Review
    • Breast reconstruction after risk-reducing mastectomy in BRCA mutation carriers.
    • Nagura N, Hayashi N, Takei J, Yoshida A, Ochi T, Iwahira Y, Yamauchi H.
    • Breast Cancer. 2019 Jul 10. doi: 10.1007/s12282-019-00995-y. [Epub ahead of print]
    • Risk-reducing surgery in BRCA1/BRCA2 mutation carriers: are there factors associated with the choice?
    • Manoukian S, Alfieri S, Bianchi E, Peissel B, Azzollini J, Borreani C.
    • Psychooncology. 2019 Jul 1. doi: 10.1002/pon.5166. [Epub ahead of print]
    • Choosing high-risk screening vs. surgery and the effect of treatment modality on anxiety and breast-specific sensuality in BRCA mutation carriers.
    • Rojas KE, Butler E, Gutierrez J, Kwait R, Laprise J, Wilbur JS, Spinette S, Raker CA, Robison K, Legare R, Gass J, Stuckey A.
    • Gland Surg. 2019 Jun;8(3):249-257. doi: 10.21037/gs.2019.04.08.
    • Residual glandular tissue (RGT) in BRCA1/2 germline mutation carriers with unilateral and bilateral prophylactic mastectomies.
    • Grinstein O, Krug B, Hellmic M, Siedek F, Malter W, Burke C, Schmutzler R, Maintz D, Rhiem K.
    • Surg Oncol. 2019 Jun;29:126-133. doi: 10.1016/j.suronc.2019.04.009. Epub 2019 May 3.
    • Factors associated with intentions for breast cancer risk management: Does risk group matter?
    • Conley CC, Agnese DM, Vadaparampil ST, Andersen BL.
    • Psychooncology. 2019 May;28(5):1119-1126. doi: 10.1002/pon.5066. Epub 2019 Apr 10.
    • Breast cancer stalked every woman in her family. She was determined it wouldn’t get her.
    • Reyes-Velarde A.
    • Los Angeles Times. Column One. 2019 Apr 25.

    Press: Behind the story: For a daughter of immigrants, a story stirs up memories of her own family. (Los Angeles Times)

    • Bilateral risk-reducing mastectomy in BRCA mutation carriers: A difficult decision-making.
    • Franceschini G, Masetti R.
    • Breast J. 2019 Apr 9. doi: 10.1111/tbj.13287. [Epub ahead of print]
    • Letter
    • Multidisciplinary management of CDH1 germinal mutation and prophylactic management hereditary lobular breast cancer: A case report.
    • Mirandola S, Pellini F, Granuzzo E, Lorenzi M, Accordini B, Ulgelmo M, Invento A, Lombardi D, Caldana M, Pollini GP.
    • Int J Surg Case Rep. 2019 Apr 5;58:92-95. doi: 10.1016/j.ijscr.2019.03.053. [Epub ahead of print]
    • What The Surgeons Should Know About The Bilateral Prophylactic Mastectomy in BRCA Mutation Carriers.
    • Franceschini G, Masetti R.
    • Eur J Breast Health. 2019 Apr 1;15(2):135-136. doi: 10.5152/ejbh.2019.4651. eCollection 2019 Apr.

    Review:

    Risk-Reducing Options for Women with a Hereditary Breast Cancer Predisposition.

    • Evolving indications and long-term oncological outcomes of risk-reducing bilateral nipple-sparing mastectomy.
    • Grobmyer SR, Pederson HJ, Valente SA, Al-Hilli Z, Radford D, Djohan R, Yetman R, Eng C, Crowe JP.
    • BJS Open. 2018 Nov 26;3(2):169-173. doi: 10.1002/bjs5.50117. eCollection 2019 Apr.
    • Body image problems in women with and without breast cancer 6-20 years after bilateral risk-reducing surgery - A prospective follow-up study.
    • Bai L, Arver B, Johansson H, Sandelin K, Wickman M, Brandberg Y.
    • Breast. 2019 Apr;44:120-127. doi: 10.1016/j.breast.2019.01.013. Epub 2019 Feb 1.
    • Current knowledge of risk reducing mastectomy: Indications, techniques, results, benefits, harms.
    • Baildam AD.
    • Breast. 2019 Mar 29;46:48-51. doi: 10.1016/j.breast.2019.03.011. [Epub ahead of print]
    • Review
    • Concerns and Expectations of Risk-Reducing Surgery in Women with Hereditary Breast and Ovarian Cancer Syndrome.
    • Modaffari P, Ponzone R, Ferrari A, Cipullo I, Liberale V, D'Alonzo M, Maggiorotto F, Biglia N.
    • J Clin Med. 2019 Mar 5;8(3). pii: E313. doi: 10.3390/jcm8030313.
    • Trends in use of bilateral prophylactic mastectomy vs high-risk surveillance in unaffected carriers of inherited breast cancer syndromes in the Inherited Cancer Registry (ICARE).
    • Henry DA, Lee MC, Almanza D, Ahmed KA, Sun W, Boulware DC, Laronga C.
    • Breast Cancer Res Treat. 2019 Feb;174(1):39-45. doi: 10.1007/s10549-018-5057-7. Epub 2018 Nov 24.
  1. s
    • Optimise not compromise: The importance of a multidisciplinary breast cancer patient pathway in the era of oncoplastic and reconstructive surgery.
    • Strach MC, Prasanna T, Kirova YM, Alran S, O'Toole S, Beith JM, Poortmans P, McNeil CM, Carroll S.
    • Crit Rev Oncol Hematol. 2019 Feb;134:10-21. doi: 10.1016/j.critrevonc.2018.11.007. Epub 2018 Nov 30.
    • Review
    • Perioperative Management of Women Undergoing Risk-reducing Surgery for Hereditary Breast and Ovarian Cancer.
    • AlHilli MM, Al-Hilli Z.
    • J Minim Invasive Gynecol. 2019 Feb;26(2):253-265. doi: 10.1016/j.jmig.2018.09.767. Epub 2018 Sep 19.
    • 'Taking Back Control': The Growth in Prophylactic Mastectomy.
    • Davenport L.
    • Medscape. Medscape Oncology. 2019 Jan 10.

    Press: 'We've Scared Women': The Growth of Prophylactic Mastectomy (Medscape Oncology)

    • Risk-Reducing Mastectomy in BRCA1 and BRCA2 Mutation Carriers: A Complex Discussion.
    • Domchek SM.
    • JAMA. 2019 Jan 1;321(1):27. doi: 10.1001/jama.2018.18942.
    • Review, Commentary
    • Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
    • Franceschini G, Di Leone A, Terribile D, Sanchez MA, Masetti R.
    • Ann Ital Chir. 2019;90:1-2.
    • Review
    • Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer.
    • Narod SA.
    • JAMA Oncol. 2018 Dec 1;4(12):1787-1788. doi: 10.1001/jamaoncol.2018.4931.
    • Letter, Comment

    Original Research:

    Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer.

    Letter, reply:

    Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer—Reply

    • Satisfaction and Impact on Quality of Life of Clinical and Instrumental Surveillance and Prophylactic Surgery in BRCA-mutation Carriers.
    • D'Alonzo M, Piva E, Pecchio S, Liberale V, Modaffari P, Ponzone R, Biglia N.
    • Clin Breast Cancer. 2018 Dec;18(6):e1361-e1366. doi: 10.1016/j.clbc.2018.07.015. Epub 2018 Jul 26.
    • Predictors of risk-reducing surgery intentions following genetic counseling for hereditary breast and ovarian cancer.
    • Ladd MK, Peshkin BN, Senter L, Baldinger S, Isaacs C, Segal H, Philip S, Phillips C, Shane K, Martin A, Weinstein V, Pilarski R, Jeter J, Sweet K, Hatten B, Wurtmann EJ, Phippen S, Bro D, Schwartz MD.
    • Transl Behav Med. 2018 Nov 10. doi: 10.1093/tbm/iby101. [Epub ahead of print]
    • Cost-effectiveness and comparative effectiveness of cancer risk management strategies in BRCA1/2 mutation carriers: a systematic review.
    • Petelin L, Trainer AH, Mitchell G, Liew D, James PA.
    • Genet Med. 2018 Oct;20(10):1145-1156. doi: 10.1038/gim.2017.255. Epub 2018 Jan 11.
    • Review
    • The development of a template for psychological assessment of women considering risk-reducing or contralateral prophylactic mastectomy: A national Delphi consensus study.
    • Braude L, Kirsten L, Gilchrist J, Juraskova I.
    • Psychooncology. 2018 Oct;27(10):2349-2356. doi: 10.1002/pon.4830. Epub 2018 Sep 4.
    • Do All BRCA 1 and 2 Carriers with a Known and Unknown Breast Cancer Choose Bilateral Mastectomies?
    • Gaffley M, Villa A, Vu T, Steelman S, Howard-McNatt M.
    • Am Surg. 2018 Sep 1;84(9):1544-1545.
    • A comparison of patient satisfaction (using the BREAST-Q questionnaire) with bilateral breast reconstruction following risk-reducing or therapeutic mastectomy.
    • Kazzazi F, Haggie R, Forouhi P, Kazzazi N, Wyld L, Malata CM.
    • J Plast Reconstr Aesthet Surg. 2018 Sep;71(9):1324-1331. doi: 10.1016/j.bjps.2018.06.011. Epub 2018 Jun 28.
    • Surgery for BRCA, TP53 and PALB2: a literature review.
    • Song CV, Teo SH, Taib NA, Yip CH.
    • Ecancermedicalscience. 2018 Aug 29;12:863. doi: 10.3332/ecancer.2018.863. eCollection 2018.
    • Breast Cancer Surgical Risk Reduction for Patients With Inherited Mutations in Moderate Penetrance Genes.
    • Weiss A, Garber JE, King T.
    • JAMA Surg. 2018 Aug 29. doi: 10.1001/jamasurg.2018.2493. [Epub ahead of print]
    • Review
    • Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer.
    • Kurian AW, Ward KC, Hamilton AS, Deapen DM, Abrahamse P, Bondarenko I, Li Y, Hawley ST, Morrow M, Jagsi R, Katz SJ.
    • JAMA Oncol. 2018 Aug 1;4(8):1066-1072. doi: 10.1001/jamaoncol.2018.0644.

    Press: Multigene Sequencing Rapidly Replacing BRCA Tests. (Medscape Oncology)

    Letter, Comment:

    Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer.

    Letter, Reply:

    Cancer Risk Estimates for Study of Multiple-Gene Testing After Diagnosis of Breast Cancer-Reply.

    • Patients' perspectives and experiences concerning barriers to accessing information about bilateral prophylactic mastectomy.
    • Glassey R, O'Connor M, Ives A, Saunders C, kConFab Investigators, O'Sullivan S, Hardcastle SJ.
    • Breast. 2018 Aug;40:116-122. doi: 10.1016/j.breast.2018.05.003. Epub 2018 May 11.
    • Breast Cancer Genetics and Indications for Prophylactic Mastectomy.
    • Krontiras H, Farmer M, Whatley J.
    • Surg Clin North Am. 2018 Aug;98(4):677-685. doi: 10.1016/j.suc.2018.03.004. Epub 2018 May 30.
    • Review
    • Prophylactic mastectomy versus surveillance for the prevention of breast cancer in women's BRCA carriers.
    • Honold F, Camus M.
    • Medwave. 2018 Jul 9;18(4):e7161. doi: 10.5867/medwave.2018.04.7160.
    • Review, Meta-Analysis, [Article in English, Spanish]
    • 'We've Scared Women': The Growth of Prophylactic Mastectomy.
    • Davenport L.
    • Medscape. Medscape Oncology. 2018 Jul 3.

    Press: 'Taking Back Control': The Growth in Prophylactic Mastectomy (Medscape Oncology)

    • Cancer risk management in Tasmanian women with BRCA1 and BRCA2 mutations.
    • Kearton S, Wills K, Bunting M, Blomfield P, James PA, Burke J.
    • Fam Cancer. 2018 Jul;17(3):333-344. doi: 10.1007/s10689-017-0047-1.
    • Hereditary lobular breast cancer with an emphasis on E-cadherin genetic defect.
    • Corso G, Figueiredo J, La Vecchia C, Veronesi P, Pravettoni G, Macis D, Karam R, Lo Gullo R, Provenzano E, Toesca A, Mazzocco K, Carneiro F, Seruca R, Melo S, Schmitt F, Roviello F, De Scalzi AM, Intra M, Feroce I, De Camilli E, Villardita MG, Trentin C, De Lorenzi F, Bonanni B, Galimberti V.
    • J Med Genet. 2018 Jul;55(7):431-441. doi: 10.1136/jmedgenet-2018-105337. Epub 2018 Jun 21.
    • Review
    • Nipple-sparing mastectomy in women at high risk of developing breast cancer.
    • Lewis RS, George A, Rusby JE.
    • Gland Surg. 2018 Jun;7(3):325-336. doi: 10.21037/gs.2018.04.01.
    • Immediate Breast Reconstruction: Comparative Outcome Study of One-Stage Direct-to-Implant and Two-Stage/Tissue Expander Techniques.
    • Meshulam-Derazon S, Shay T, Lewis S, Adler N.
    • Isr Med Assoc J. 2018 Jun;20(6):340-344.
    • Juliet's story: No reconstruction is a post-mastectomy option.
    • [No author given]
    • FORCE. XRAYS. 2018 May 24.

    Blog post: I felt empowered by choosing not to have a reconstruction. (Breast Cancer Care)

    • The Relationship Between Body Image, Gender, Subjective Norms, and the Decision to Undergo Preventive Mastectomy Among Arab and Jewish BRCA Carriers.
    • Kardosh M, Bar-Tal Y, Barnoy S.
    • Cancer Nurs. 2018 May/Jun;41(3):255-262. doi: 10.1097/NCC.0000000000000503.
    • Risk management decisions in women with BRCA1 and BRCA2 mutations.
    • Morgan R, Brown A, Hamman KJ, Sampson J, Naik A, Massimino K.
    • Am J Surg. 2018 May;215(5):899-903. doi: 10.1016/j.amjsurg.2018.02.010. Epub 2018 Feb 13.
    • Risk-reducing mastectomy for the prevention of primary breast cancer.
    • Carbine NE, Lostumbo L, Wallace J, Ko H.
    • Cochrane Database Syst Rev. 2018 Apr 5;4:CD002748. doi: 10.1002/14651858.CD002748.pub4.
    • Review, Meta-Analysis

    Summary: Women should be aware of their true risk of developing breast cancer and the limitations of current evidence when considering risk-reducing mastectomy. (Cochrane Library)

    • Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation.
    • Müller D, Danner M, Rhiem K, Stollenwerk B, Engel C, Rasche L, Borsi L, Schmutzler R, Stock S.
    • Eur J Health Econ. 2018 Apr;19(3):341-353. doi: 10.1007/s10198-017-0887-5. Epub 2017 Apr 5.
    • When BRCA Mutations Meet Complications.
    • Clausen AM.
    • Global Health NOW. 2018 Mar 20.
    • Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
    • Yamauchi H, Nakagawa C, Kobayashi M, Kobayashi Y, Mano T, Nakamura S, Arai M.
    • Breast Cancer. 2018 Mar;25(2):141-150. doi: 10.1007/s12282-017-0803-y. Epub 2017 Oct 10.
    • Prophylactic mastectomy for BRCA mutation carriers after ovarian cancer treatment: is it beneficial?
    • Kotsopoulos J, Narod SA.
    • Expert Rev Anticancer Ther. 2018 Mar;18(3):199-200. doi: 10.1080/14737140.2018.1424547. Epub 2018 Jan 8.
    • Oncologic Safety of Prophylactic Nipple-Sparing Mastectomy in a Population With BRCA Mutations: A Multi-institutional Study.
    • Jakub JW, Peled AW, Gray RJ, Greenup RA, Kiluk JV, Sacchini V, McLaughlin SA, Tchou JC, Vierkant RA, Degnim AC, Willey S.
    • JAMA Surg. 2018 Feb 1;153(2):123-129. doi: 10.1001/jamasurg.2017.3422.

    Commentary:

    When is a Little Breast Tissue Too Much?: Nipple-Sparing Risk-Reducing Mastectomy in BRCA Carriers.

    • Perspectives of Women Considering Bilateral Prophylactic Mastectomy and their Peers towards a Telephone-Based Peer Support Intervention.
    • St-Pierre D, Bouchard K, Gauthier L, Chiquette J, Dorval M; Centre ROSE.
    • J Genet Couns. 2018 Feb;27(1):274-288. doi: 10.1007/s10897-017-0148-x. Epub 2017 Sep 15.
    • The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy.
    • Giannakeas V, Narod SA.
    • Breast Cancer Res Treat. 2018 Jan;167(1):263-267. doi: 10.1007/s10549-017-4476-1. Epub 2017 Sep 15.
    • Risk-Reducing Mastectomy and Breast Reconstruction: Indications and Evidence for Current Management Strategies.
    • Eisemann BS, Spiegel AJ.
    • Clin Plast Surg. 2018 Jan;45(1):129-136. doi: 10.1016/j.cps.2017.08.013. Epub 2017 Sep 29.
    • Review
    • Heightened perception of breast cancer risk in young women at risk of familial breast cancer.
    • Glassey R, O'Connor M, Ives A, Saunders C; kConFab Investigators, O'Sullivan S, Hardcastle SJ.
    • Fam Cancer. 2018 Jan;17(1):15-22. doi: 10.1007/s10689-017-0001-2.
    • The Preventive Intervention of Hereditary Breast Cancer.
    • Cao A, Huang L, Shao Z.
    • Adv Exp Med Biol. 2017 [2017 Dec 28];1026:41-57. doi: 10.1007/978-981-10-6020-5_3.
    • Review
    • Facilitating decision-making in women undergoing genetic testing for hereditary breast cancer: BRECONDA randomized controlled trial results.
    • Sherman KA, Kilby CJ, Shaw LK, Winch C, Kirk J, Tucker K, Elder E.
    • Breast. 2017 Dec;36:79-85. doi: 10.1016/j.breast.2017.10.001. Epub 2017 Oct 12.
    • Nipple-Sparing Mastectomy and Its Application on BRCA Gene Mutation Carrier.
    • Co M, Chiu R, Chiu TM, Chong YC, Lau S, Lee YH, To HM, Kwong A.
    • Clin Breast Cancer. 2017 Dec;17(8):581-584. doi: 10.1016/j.clbc.2017.02.001. Epub 2017 Feb 14.
    • Review
    • [Current German and American guidelines for autologous fat grafting - a transatlantic comparison].
    • Broelsch GF, Könneker S, Ipaktchi R, Vogt PM.
    • Handchir Mikrochir Plast Chir. 2017 Dec;49(6):408-414. doi: 10.1055/s-0043-118595. Epub 2017 Dec 29.
    • [Article in German]
    • When to Consider Risk-Reducing Mastectomy in BRCA1/BRCA2 Mutation Carriers with Advanced Stage Ovarian Cancer: a Case Study Illustrating the Genetic Counseling Challenges.
    • Speight B, Tischkowitz M.
    • J Genet Couns. 2017 Dec;26(6):1173-1178. doi: 10.1007/s10897-017-0136-1. Epub 2017 Aug 5.
    • Genetics of Breast and Gynecologic Cancers (PDQ®): Health Professional Version. Psychosocial Issues in Inherited Breast and Ovarian Cancer Syndromes. Psychosocial Outcome Studies.
    • PDQ Cancer Genetics Editorial Board.
    • PDQ Cancer Information Summaries [Internet]. Bethesda, MD: National Cancer Institute. Updated 2017 Nov 30. Accessed 2017 Dec 8.
    • Patient experience with breast reconstruction process following bilateral mastectomy in BRCA mutation carriers.
    • Nurudeen S, Guo H, Chun Y, Coopey S, Barry W, Garber J, Dominici LS.
    • Am J Surg. 2017 Oct;214(4):687-694. doi: 10.1016/j.amjsurg.2017.06.017. Epub 2017 Jun 28.
    • Management of Breast Cancer Risk in Women with Ovarian Cancer and Deleterious BRCA1 or BRCA2 Mutations.
    • Wahner Hendrickson AE, Bakkum-Gamez JN, J Couch F, Ghosh K, Boughey JC.
    • Ann Surg Oncol. 2017 Oct;24(11):3107-3109. doi: 10.1245/s10434-017-5999-8. Epub 2017 Jul 20.

    Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer.

    • Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer.
    • Gamble C, Havrilesky LJ, Myers ER, Chino JP, Hollenbeck S, Plichta JK, Kelly Marcom P, Shelley Hwang E, Kauff ND, Greenup RA.
    • Ann Surg Oncol. 2017 Oct;24(11):3116-3123. doi: 10.1245/s10434-017-5995-z. Epub 2017 Jul 11.

    Editorial:

    Management of Breast Cancer Risk in Women with Ovarian Cancer and Deleterious BRCA1 or BRCA2 Mutations.

    • Differences Among a Modern Cohort of BRCA Mutation Carriers Choosing Bilateral Prophylactic Mastectomies Compared to Breast Surveillance.
    • Gilbert E, Zabor EC, Stempel M, Mangino D, Heerdt A, Pilewskie M.
    • Ann Surg Oncol. 2017 Oct;24(10):3048-3054. doi: 10.1245/s10434-017-5976-2. Epub 2017 Aug 1.
    • Clinical Decision-Making in Patients with Variant of Uncertain Significance in BRCA1 or BRCA2 Genes.
    • Welsh JL, Hoskin TL, Day CN, Thomas AS, Cogswell JA, Couch FJ, Boughey JC.
    • Ann Surg Oncol. 2017 Oct;24(10):3067-3072. doi: 10.1245/s10434-017-5959-3. Epub 2017 Aug 1.
    • Qualitatively understanding patients' and health professionals' experiences of the BRECONDA breast reconstruction decision aid.
    • Sherman KA, Shaw LK, Jørgensen L, Harcourt D, Cameron L, Boyages J, Elder E, Kirk J, Tucker K.
    • Psychooncology. 2017 Oct;26(10):1618-1624. doi: 10.1002/pon.4346. Epub 2017 Jan 30.
    • Quality of Patient Decisions About Breast Reconstruction After Mastectomy.
    • Lee CN, Deal AM, Huh R, Ubel PA, Liu YJ, Blizard L, Hunt C, Pignone MP.
    • JAMA Surg. 2017 Aug 1;152(8):741-748. doi: 10.1001/jamasurg.2017.0977.
    • Risk Reduction Strategies in Breast Cancer Prevention.
    • Costa M, Saldanha P.
    • Eur J Breast Health. 2017 Jul 1;13(3):103-112. doi: 10.5152/ejbh.2017.3583. eCollection 2017 Jul.
    • Managing hereditary breast cancer risk in women with and without ovarian cancer.
    • Peters ML, Garber JE, Tung N.
    • Gynecol Oncol. 2017 Jul;146(1):205-214. doi: 10.1016/j.ygyno.2017.04.013. Epub 2017 Apr 25.
    • Review
    • Women at familial risk of breast cancer electing for prophylactic mastectomy: frequencies, procedures, and decision-making characteristics.
    • Schott S, Vetter L, Keller M, Bruckner T, Golatta M, Eismann S, Dikow N, Evers C, Sohn C, Heil J.
    • Arch Gynecol Obstet. 2017 Jun;295(6):1451-1458. doi: 10.1007/s00404-017-4376-y. Epub 2017 Apr 24.
    • Patient and medical barriers preclude uptake of tamoxifen preventative therapy in women with a strong family history.
    • Skandarajah AR, Thomas S, Shackleton K, Chin-Lenn L, Lindeman GJ, Mann GB.
    • Breast. 2017 Apr;32:93-97. doi: 10.1016/j.breast.2017.01.002. Epub 2017 Jan 18.
    • Women's preferences for contralateral prophylactic mastectomy following unilateral breast cancer: What risk-reduction makes it worthwhile?
    • Tesson S, Richards I, Porter D, Phillips KA, Rankin N, Costa D, Musiello T, Marven M, Butow P.
    • Breast. 2017 Feb;31:233-240. doi: 10.1016/j.breast.2016.11.025. Epub 2016 Dec 13.
    • Commentary: Bilateral risk-reducing mastectomy is the safest strategy in BRCA1 carriers.
    • Glassey R, Saunders C, Hardcastle SJ.
    • Front Psychol. 2017 Jan 31;8:121. doi: 10.3389/fpsyg.2017.00121. eCollection 2017.

    Review:

    Bilateral risk-reducing mastectomy is the safest strategy in BRCA1 carriers

    • Psychological factors associated with the intention to choose for risk-reducing mastectomy in family cancer clinic attendees.
    • van Driel CM, Oosterwijk JC, Meijers-Heijboer EJ, van Asperen CJ, Zeijlmans van Emmichoven IA, de Vries J, Mourits MJ, Henneman L, Timmermans DR, de Bock GH.
    • Breast. 2016 Dec;30:66-72. doi: 10.1016/j.breast.2016.08.016. Epub 2016 Sep 14.
    • Prophylactic Bilateral Nipple-sparing Mastectomy and a Staged Breast Reconstruction Technique: Preliminary Results.
    • Tondu T, Thiessen F, Tjalma WA.
    • Breast Cancer (Auckl). 2016 Nov 9;10:185-189. eCollection 2016.
    • Users' guide to the surgical literature: how to assess an article about harm in surgery.
    • Thoma A, Kaur MN, Farrokhyar F, Waltho D, Levis C, Lovrics P, Goldsmith CH.
    • Can J Surg. 2016 Sep;59(5):351-357.
    • Trends in Breast Reconstruction by Ethnicity: An Institutional Review Centered on the Treatment of an Urban Population.
    • Rodby KA, Danielson KK, Shay E, Robinson E, Benjamin M, Antony AK.
    • Am Surg. 2016 Jun;82(6):497-504.
    • Prophylactic mastectomy: insights from women who chose to reduce their risk by Andrea Farkas Patenaude, PhD Praeger 2012. 227 ps. ISBN: 0313345163.
    • Lisa R. Rubin, Kailey Roberts.
    • Psycho-Oncology. 25(6):747-8. doi: 10.1002/pon.4152. 2016 Jun.
    • Book review
    • Iranian women's attitude toward prophylactic mastectomy for breast cancer.
    • Majidzadeh-A K, Farahmand L, Zare AA, Esmaeili R, Salehi M, Habibi M.
    • J Cancer Res Ther. 2016 Apr-Jun;12(2):915-9. doi: 10.4103/0973-1482.171363.
    • Is Sentinel Lymph Node Biopsy Necessary in Patients Undergoing Prophylactic Mastectomy? A Systematic Review and Meta-Analysis.
    • Nagaraja V, Edirimanne S, Eslick GD.
    • Breast J. 2016 Mar-Apr;22(2):158-65. doi: 10.1111/tbj.12549. Epub 2016 Jan 8.
    • Meta-Analysis
    • Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis.
    • Basu NN, Ingham S, Hodson J, Lalloo F, Bulman M, Howell A, Evans DG.
    • Fam Cancer. 2015 Dec;14(4):531-8. doi: 10.1007/s10689-015-9825-9.
    • A Woman's Decision to Choose Bilateral Mastectomy.
    • Jerome-D'Emilia B, Suplee PD, Boiler JL, D'Emilia JC.
    • Cancer Nurs. 2015 Nov-Dec;38(6):426-35. doi: 10.1097/NCC.0000000000000232.
    • Nipple-sparing mastectomy in patients with BRCA1/2 mutations and variants of uncertain significance.
    • Manning AT, Wood C, Eaton A, Stempel M, Capko D, Pusic A, Morrow M, Sacchini V.
    • Br J Surg. 2015 Oct;102(11):1354-9. doi: 10.1002/bjs.9884. Epub 2015 Aug 27.
    • Podcast: Prophylactic Surgery Decisions Before BRCA Testing.
    • [No author given]
    • My Gene Counsel. 2015 Sep 29.
    • Risk assessment: Physicians discuss motivations for rising rates of prophylactic mastectomies.
    • Printz C.
    • Cancer. 2015 Jun 1;121(11):1721-2. doi: 10.1002/cncr.28996.
    • Bilateral Prophylactic Mastectomy Rarely Cost-effective.
    • Pam Harrison.
    • Medscape Medical News. American Society of Breast Surgeons (ASBS) 16th Annual Meeting. 2015 May 1.
    • The relationship between the belief in a genetic cause for breast cancer and bilateral mastectomy.
    • Petrie KJ, Myrtveit SM, Partridge AH, Stephens M, Stanton AL.
    • Health Psychol. 2015 May;34(5):473-6. doi: 10.1037/hea0000118. Epub 2014 Aug 18.
    • A MDP Model for Breast and Ovarian Cancer Intervention Strategies for BRCA1/2 Mutation Carriers.
    • Abdollahian M, Das TK.
    • IEEE J Biomed Health Inform. 2015 Mar;19(2):720-7. doi: 10.1109/JBHI.2014.2319246. Epub 2014 Apr 22.
    • Prophylactic mastectomy: Who needs it, when and why.
    • Burke EE, Portschy PR, Tuttle TM.
    • J Surg Oncol. 2015 Jan;111(1):91-5. doi: 10.1002/jso.23695. Epub 2014 Jun 25.
    • Review
    • Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling.
    • Tong A, Kelly S, Nusbaum R, Graves K, Peshkin BN, Valdimarsdottir HB, Wood M, McKinnon W, Garber J, McCormick SR, Jandorf L, Schwartz MD.
    • Psychooncology. 2015 Jan;24(1):33-9. doi: 10.1002/pon.3560. Epub 2014 May 17.
    • Impact of Prophylactic Mastectomy in BRCA1/2 Mutation Carriers.
    • Rhiem K, Schmutzler R.
    • Breast Care (Basel). 2014 Dec;9(6):385-9. doi: 10.1159/000369592.
    • Informed decision-making is the key in women at high risk of breast cancer.
    • Taylor A, Tischkowitz M.
    • Eur J Surg Oncol. 2014 Jun;40(6):667-9. doi: 10.1016/j.ejso.2014.02.219. Epub 2014 Feb 17.
    • Bilateral risk-reducing mastectomy is the safest strategy in BRCA1 carriers.
    • Pilgrim S, Pain S.
    • Eur J Surg Oncol. 2014 Jun;40(6):670-2. doi: 10.1016/j.ejso.2014.02.218. Epub 2014 Feb 18.
    • Review

    Comment:

    Commentary: Bilateral risk-reducing mastectomy is the safest strategy in BRCA1 carriers.

    • Changes in specialists' perspectives on cancer genetic testing, prophylactic surgery and insurance discrimination: then and now.
    • Matloff ET, Bonadies DC, Moyer A, Brierley KL.
    • J Genet Couns. 2014 Apr;23(2):164-71. doi: 10.1007/s10897-013-9625-z. Epub 2013 Jul 13.

    Press: What’s Ahead for BRCA Genetic Testing and Counseling? (OncLive)

    • Impact of rapid genetic counselling and testing on the decision to undergo immediate or delayed prophylactic mastectomy in newly diagnosed breast cancer patients: findings from a randomised controlled trial.
    • Wevers MR, Aaronson NK, Verhoef S, Bleiker EM, Hahn DE, Kuenen MA, van der Sanden-Melis J, Brouwer T, Hogervorst FB, van der Luijt RB, Valdimarsdottir HB, van Dalen T, Theunissen EB, van Ooijen B, de Roos MA, Borgstein PJ, Vrouenraets BC, Vriens E, Bouma WH, Rijna H, Vente JP, Witkamp AJ, Rutgers EJ, Ausems MG.
    • Br J Cancer. 2014 Feb 18;110(4):1081-7. doi: 10.1038/bjc.2013.805. Epub 2014 Jan 14.
    • Risk-reducing mastectomy in BRCA1/2 mutation carriers: Factors influencing uptake and timing.
    • van Driel CM, Eltahir Y, de Vries J, Jaspers JP, Oosterwijk JC, Mourits MJ, de Bock GH.
    • Maturitas. 2014 Feb;77(2):180-4. doi: 10.1016/j.maturitas.2013.10.017. Epub 2013 Nov 1.
    • Angelina's choice: private decision, public impact.
    • Sirohi B, Sinha N, Goel NS, Badwe RA.
    • Indian J Med Ethics. 2014 Jan-Mar;11(1):34-5.
    • Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers.
    • Singh K, Lester J, Karlan B, Bresee C, Geva T, Gordon O.
    • Am J Obstet Gynecol. 2013 Apr;208(4):329.e1-6. doi: 10.1016/j.ajog.2013.01.026. Epub 2013 Jan 17.
    • Prophylactic mastectomy: an appraisal.
    • Zagouri F, Chrysikos DT, Sergentanis TN, Giannakopoulou G, Zografos CG, Papadimitriou CA, Zografos GC.
    • Am Surg. 2013 Feb;79(2):205-12.
    • Review
    • Anticipatory loss and early mastectomy for young female BRCA1/2 mutation carriers.
    • Hoskins LM, Greene MH.
    • Qual Health Res. 2012 Dec;22(12):1633-46. doi: 10.1177/1049732312458182. Epub 2012 Aug 27.
    • 'Cancer doesn't have an age': Genetic testing and cancer risk management in BRCA1/2 mutation-positive women aged 18-24.
    • Werner-Lin A, Hoskins LM, Doyle MH, Greene MH.
    • Health (London). 2012 Nov;16(6):636-54. doi: 10.1177/1363459312442420. Epub 2012 Apr 30.
    • Role of Breast Surgery in BRCA Mutation Carriers.
    • Nestle-Krämling C, Kühn T.
    • Breast Care (Basel). 2012 Oct;7(5):378-82. doi: 10.1159/000343717.
    • Comparison of patient characteristics and outcomes of contralateral prophylactic mastectomy and unilateral total mastectomy in breast cancer patients.
    • Chung A, Huynh K, Lawrence C, Sim MS, Giuliano A.
    • Ann Surg Oncol. 2012 Aug;19(8):2600-6. doi: 10.1245/s10434-012-2299-1. Epub 2012 Mar 7.
    • How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diagnosed with breast cancer.
    • Watts KJ, Meiser B, Mitchell G, Kirk J, Saunders C, Peate M, Duffy J, Kelly PJ, Gleeson M, Barlow-Stewart K, Rahman B, Friedlander M, Tucker K; TFGT Collaborative Group.
    • BMC Cancer. 2012 Jul 28;12:320. doi: 10.1186/1471-2407-12-320.
    • [Present status and tasks for genetic testing and risk-reducing surgery in patients with hereditary breast and ovarian cancer].
    • Arai M, Taki K, Iwase H, Takizawa K, Nishimura S, Iwase T.
    • Gan To Kagaku Ryoho. 2012 Apr;39(4):525-31.
    • [Article in Japanese]
    • Online tool to guide decisions for BRCA1/2 mutation carriers.
    • Kurian AW, Munoz DF, Rust P, Schackmann EA, Smith M, Clarke L, Mills MA, Plevritis SK.
    • J Clin Oncol. 2012 Feb 10;30(5):497-506. doi: 10.1200/JCO.2011.38.6060. Epub 2012 Jan 9.

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: An Online BRCA Positive Decision Guidance Tool.

    Comment:

    Are we ready for online tools in decision making for BRCA1/2 mutation carriers?

    Press: Are We Ready for Online Tools in Decision Making for BRCA1/2 Mutation Carriers? (Journal of Clinical Oncology)

    Press: Online tool helps those with BRCA mutations understand options. (Medical Xpress)

    • What made her give up her breasts: a qualitative study on decisional considerations for contralateral prophylactic mastectomy among breast cancer survivors undergoing BRCA1/2 genetic testing.
    • Kwong A, Chu AT.
    • Asian Pac J Cancer Prev. 2012;13(5):2241-7.